T1 Tissue Mapping as a Non Invasive Biomarker for Quantification of Chronic Thyroid Related Microscopic Myocardial Fibrosis.

November 18, 2025 updated by: Lina Mohamed Farid, Assiut University
CMR T1 tissue mapping helps in detection and quantification of the microscopic myocardial fibrosis and is more accurate and non invasive maneuver.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Chronic thyroid diseased patients either hypo or hyperthyroidism may develop arrhythmias or even atrial fibrillation which is worrisome. And since early detection provides the early management, T1 tissue mapping of the heart provides accurate quantification of the myocardial fibrosis throughout the imaged organ.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Hypo and hyperthyroidism in both genders.

Description

Inclusion Criteria:

  • patients with chronic thyroid disease.

Exclusion Criteria:

  • patients with other chronic illnesses ( diabetes, hypertension, .. etc).
  • patients received neck radiation therapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myocardial fibrosis
Time Frame: 1 year
Detection and quantification of myocardial fibrosis.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

November 18, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Actual)

November 25, 2025

Study Record Updates

Last Update Posted (Actual)

November 25, 2025

Last Update Submitted That Met QC Criteria

November 18, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • CMR T1 tissue mapping

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Thyroid Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe